C83.39
Diffuse large B-cell lymphoma, extranodal and solid organ sites
Clinical Classification Guidelines
Medical Intelligence & Overview
Diffuse large B-cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma, which is a cancer that originates in the lymphatic system. This specific subtype, coded as C83.39 in the ICD-10 classification, refers to DLBCL affecting extranodal sites and solid organs outside of the lymph nodes. It is a fast-growing, aggressive form of lymphoma that can occur in various organs, leading to significant health concerns if not diagnosed and treated promptly. Understanding the nature of this condition helps in recognizing its importance and the need for specialized medical care.
Causes & Symptoms
Clinical Causes: Genetic mutations that cause abnormal B-cell growth Exposure to certain chemicals or toxins History of immune system suppression or immunodeficiency Possible association with viral infections such as HIV or Epstein-Barr virus Older age, which increases risk Family history of lymphoma or other hematologic cancers
Key Symptoms: Rapidly enlarging mass or swelling in affected organs Fever that persists or recurs without an apparent cause Unexplained weight loss Night sweats, especially intense or frequent Fatigue or general feeling of weakness Pain or discomfort in the affected area Itching or skin changes if the lymphoma involves the skin or subcutaneous tissue Breathing difficulties if the lungs or mediastinal areas are involved
Diagnostic & Treatment
Diagnosis Path: Medical history review and physical examination to identify visible or palpable masses Imaging tests such as CT scans, PET scans, or MRI to determine the location and spread of the disease Biopsy of the affected tissue or organ to confirm the presence of lymphoma cells and determine their type Laboratory tests, including blood tests, to assess overall health and organ function Molecular and immunohistochemical studies to classify the lymphoma subtype accurately
Treatment Protocols: Chemotherapy, often with regimens like R-CHOP, which includes rituximab and other anti-cancer drugs Targeted therapies aimed at specific markers on lymphoma cells Radiation therapy in selected cases, especially if localized Stem cell transplantation may be considered in relapsed or refractory cases Supportive care to manage symptoms, side effects, and maintain overall health
Clinical Advice & FAQs
Billing Guidance
Is C83.39 a billable ICD-10 code?
Yes, C83.39 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C83.39?
Clinical documentation must specify the nature of Diffuse large B-cell lymphoma, extranodal and solid organ sites and any associated comorbidities for accurate reporting.
Cite this Clinical Reference